ThyroSeq v3 involves targeted next-generation sequencing analysis of 112 cancer-related genes for point mutations, gene fusions, copy number alterations, or abnormal gene expression (such as BRAF and RAS and PAX8—PPARG/RET—PTC) [13,14]. This evidence concerns the gene RET and cancer.